- Home
- MGNX vs QH Comparison
MGNX vs QH Comparison
Compare MGNX & QH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- QH
- Stock Information
- Founded
- MGNX 2000
- QH 2012
- Country
- MGNX United States
- QH China
- Employees
- MGNX N/A
- QH N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- QH Business Services
- Sector
- MGNX Health Care
- QH Consumer Discretionary
- Exchange
- MGNX Nasdaq
- QH Nasdaq
- Market Cap
- MGNX 87.7M
- QH 104.9M
- IPO Year
- MGNX 2013
- QH 2020
- Fundamental
- Price
- MGNX $1.25
- QH $1.23
- Analyst Decision
- MGNX Hold
- QH
- Analyst Count
- MGNX 9
- QH 0
- Target Price
- MGNX $5.33
- QH N/A
- AVG Volume (30 Days)
- MGNX 2.6M
- QH 7.5K
- Earning Date
- MGNX 08-05-2025
- QH 04-29-2025
- Dividend Yield
- MGNX N/A
- QH N/A
- EPS Growth
- MGNX N/A
- QH N/A
- EPS
- MGNX N/A
- QH 0.01
- Revenue
- MGNX $154,050,000.00
- QH $417,431,053.00
- Revenue This Year
- MGNX N/A
- QH N/A
- Revenue Next Year
- MGNX N/A
- QH N/A
- P/E Ratio
- MGNX N/A
- QH $134.71
- Revenue Growth
- MGNX 255.31
- QH N/A
- 52 Week Low
- MGNX $0.99
- QH $0.25
- 52 Week High
- MGNX $5.77
- QH $2.27
- Technical
- Relative Strength Index (RSI)
- MGNX 37.88
- QH 52.11
- Support Level
- MGNX $1.19
- QH $1.16
- Resistance Level
- MGNX $1.41
- QH $1.30
- Average True Range (ATR)
- MGNX 0.12
- QH 0.04
- MACD
- MGNX -0.03
- QH 0.02
- Stochastic Oscillator
- MGNX 4.85
- QH 51.22
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.